Lung Cancer Clinical Trials

Showing 3001-3020 of 4,288 trials

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

NCT03228277

The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from extracellular vesicles of bronchoalveolar lavage fluid.

Non Small Cell Lung Cancer

Konkuk University Medical Center25 participantsStarted Jul 2017

Seoul, South Korea

COMPLETEDPhase 1

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007

NCT01061788

This open-label, non-randomized, dose escalation phase I biomarker trial of the triplet regimen of AMG 479, everolimus, and panitumumab for subjects with refractory advanced solid tumors is designed to assess the safety and tolerability of this combination as well as preliminary efficacy.

Advanced Solid Tumors, Non-small Cell Lung Cancer

Jeffrey Clarke43 participantsStarted Apr 2010

Durham, North Carolina, United States

TERMINATEDPhase 2

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

NCT02275806

This is a prospective, single institution phase II study, whose primary objective is to estimate the median and three year survival rate of non-small lung cancer patients with Stage IIIA and IIIB intra-thoracic disease which is referred to as "locally advanced" non-small cell lung cancer (NSCLC).

Lung Neoplasms, Non-Small Cell Lung Cancer

Leo W. Jenkins Cancer Center4 participantsStarted Oct 2014

Greenville, North Carolina, United States

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Related Searches

Evaluation of the Impact of a Coordinating Nurse in a Personalized Care Program on Quality of Care, Coordination of the Actors and on Quality of Life for Patients With Lung Cancer

Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.

Detection of Circulating Biomarkers of Immunogenic Cell Death

Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

3D Printing for Nodule Localization

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Reducing Insulin, Growth Hormones, and Tumors

Pulmonary Nodule Cohort

Prospective Analysis of Robot-Assisted Surgery

Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Improving Compliance With Medical Testing Guidelines

Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.